Revance has strategically identified unique partnerships to reinforce our product pipeline
In partnership with Viatris Inc. (formerly known as Mylan N.V.), Revance is developing a biosimilar to BOTOX®, which would allow Revance to compete in the existing short-acting neuromodulator marketplace, while focusing commercial efforts on creating a new, longer-acting neuromodulator category.
BOTOX® is a registered trademark of Allergan, Inc
China Market License
We entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), providing Fosun Pharma Industrial with the exclusive rights to develop and commercialize daxibotulinumtoxinA-lanm injection in mainland China, Hong Kong and Macau (the Territory). In the second quarter of 2021 Fosun Pharma initiated Phase 3 trials of daxibotulinumtoxinA-Ianm in China for the treatment of glabellar lines and cervical dystonia.
If you are interested in pursuing a corporate partnership please contact us by filling out the form below:
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY™ and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY™ is not approved for the treatment of spasticity or any conditions other than glabellar lines.
IMPORTANT SAFETY INFORMATION
DAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Co-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.
Use in Specific Populations
DAXXIFY™ is not recommended for use in children or pregnant women.